Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors

Urologia. 2014 Apr-Jun;81(2):120-4. doi: 10.5301/uro.5000031. Epub 2013 Nov 29.

Abstract

Introduction: To research the importance of the neutrophil-to-lymphocyte ratio (NLR) in muscle-invasive bladder cancers (MIBC) and non-muscle invasive bladder cancer (NMIBC).

Methods: Data of 198 patients who underwent TUR-TM in our clinic were retrospectively evaluated. Patients were divided into two groups: group-I (MIBC) and group-II (NMIBC). The neutrophil and lymphocyte counts, NLR, hemoglobin and hematocrit values, tumor numbers, sizes and degrees of patients were recorded. Within the inter-group comparison, Mann-Whitney U test was used for the values stated with measuring, whereas a Chi-square test was used for the values stated with counting. The cut-off value for the NLR was determined with ROC curve.

Results: The NLR values of group-I and group-II were found as 4.14 ± 2.76 and 3.36 ± 2.88, respectively (p = 0.03). Whether the NLR carries a differential property was evaluated with ROC curve. The cut-off value was estimated as 3.96 according to the Youden index. With this value, sensitivity was found as 50%, specificity was 22.8% and AUC was 0.615 (p = 0.03).

Discussion: According to the data in this study, it can be said that Ta-T1 tumors are likely to be invasive by 50% if the NLR value is greater than 3.96.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Papillary / immunology
  • Carcinoma, Papillary / pathology*
  • Carcinoma, Transitional Cell / immunology
  • Carcinoma, Transitional Cell / pathology*
  • Female
  • Humans
  • Leukocyte Count
  • Lymphocyte Count
  • Lymphocytes, Tumor-Infiltrating / pathology*
  • Male
  • Middle Aged
  • Muscle, Smooth / immunology
  • Muscle, Smooth / pathology*
  • Neoplasm Invasiveness / immunology*
  • Neoplasm Staging
  • Neutrophil Infiltration*
  • ROC Curve
  • Retrospective Studies
  • Sensitivity and Specificity
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / pathology*